

RIZGAR A MAGEED

TITLE OF EMPLOYMENT: **VISITING PROFESSOR**
SCIENTIFIC TITLE: **PROFESSOR**
COLLEGE: **PHARMACY**
NUMBER OF THE ROOM: **G8**

CONTACT

r.a.mageed@qmul.ac.uk

Tel +44(0)207-882-3989

https://www.qmul.ac.uk/whri/people/academic-staff/items/mageedrizgar.html

Rizgar Mageed first qualified from the College of Pharmacy at Baghdad University in 1976. He was awarded his PhD at the Royal London Hospital Medical School, London University in 1985. He was appointed Research Fellow at the Department of Immunology University of Birmingham Medical School in 1984 where he worked until 1990 and then joined the Kennedy Institute of Rheumatology as a Senior Scientist. In 1996, Rizgar was appointed Senior Lecturer at Imperial College. In 2000, Rizgar was awarded Arthritis Research-UK Fellowship and appointed Senior Lecturer at the Centre for Rheumatology at University College London. Rizgar joined Queen Mary University of London in May 2003. In 2009 Rizgar become a fellow of the Royal College of Pathologists (FRCPath) and in 2014 was awarded his fellowship by the Royal College of Physicians (FRCP).

Research areas and most important published research

Church MK, **Mageed RA**, Holgate ST. Human tonsillar mast cells: characteristics of histamine secretion and methods of dispersion. **Int Arch Allergy Appl Immunol 1983; 72: 188-90.**

2. Bourne JT, Kumar P, Huskisson EC, **Mageed RA**, Unsworth DJ, Wojtulewski JA. Arthritis and coeliac disease. **Ann Rheum Dis 1985; 44: 592-8.**

3. Kirk AP, O'Hara BP, **Mageed RA**, McMahon MS, McCarthy DS, Menashi S, Archer JR, Currey HLF. Pepsinogen-: an immunoglobulin binding artefact in "collagen" preparations. **Clin Exp Immunol 1986; 65: 671-8.**

4. **Mageed RA,** Dearlove M, Goodall DM, Jefferis R. Immunogenic and antigenic epitopes of immunoglobulins. XVII. Monoclonal antibodies reactive with common and restricted idiotopes on the heavy chain of human rheumatoid factor. **Rheumatol Int 1986; 6: 179-83.**

5. **Mageed RA**, Walker MR, Jefferis R. Restricted light chain subgroup expression in human rheumatoid factor paraproteins determined by monoclonal antibodies. **Immunol 1986; 59: 473-8.**

6. **Mageed RA**, Jefferis R. Molecular specificity and idiotypy of human rheumatoid factors. **Monographs in Allergy 1987; 22: 24-30.**

7. Newkirk MM, **Mageed RA**, Jefferis R, Chen PP, Capra JD. Complete amino acid sequences of variable regions of two human rheumatoid factors, BOR and KAS of the Wa idiotypic family, reveal restricted use of heavy and light chain variable and joining region gene segments. **J Exp Med 1987; 166: 550-64.**

8. Jose SA, Griffiths H, Lunec J, **Mageed RA**, Jefferis R. Immunogenic and antigenic epitopes of immunoglobulins. XX. Denaturation of human IgG3 by free radicals. **Mol Immunol 1987; 24: 1145-50.**

9. Jones VE, Puttick AH, Williamson EA, **Mageed RA**. A new assay uses monoclonal anti-Rh (D) antibodies to determine rheumatoid factor specificity. I. Reactivity to a monoclonal antibody of the G3m (21) is more frequent in rheumatoid patients negative for G3m (21). **Clin Exp Immunol 1988; 71: 451-8.**

10. Crowley JJ, Goldfien RD, Schrohenloher RE, Spiegelberg HL, **Mageed RA**, Jefferis R, Koopman WJ, Carson DA, Fong S. 1988. Incidence of two cross-reactive idiotype defines two mutually exclusive kappa light chain variable region subgroups for human rheumatoid factor paraproteins. **J Immunol 1988; 140: 3411-8.**

11. Silverman GJ, Goldfien RD, Chen PP, **Mageed RA**, Jefferis R, Goni F, Frangione B, Fong S, Carson DA. Idiotypic and subgroup analysis of human monoclonal rheumatoid factors. Implications for structural and genetic basis of auto antibodies in humans. **J Clin Invest 1988; 82: 469-75.**

12. **Mageed RA**, Carson DA, Jefferis R. 1988. Analysis of rheumatoid factor autoantibodies in patients with essential mixed cryoglobulinaemia and rheumatoid arthritis. **Scand J Rheumatol 1988; S75: 172-8.**

13. **Mageed RA**, Carson DA, Jefferis R. Immunogenic and antigenic epitopes of immunoglobulins. XXIII. Idiotypy and molecular specificity of human rheumatoid factors: analysis of cross-reactive idiotype of rheumatoid factor paraproteins from the Wa idiotypic group in relation to their IgG subclass specificity. **Scand J Immunol 1988; 28: 233-40.**

14. Jefferis R, **Mageed RA**. The epitope specificity and idiotypy of monoclonal rheumatoid factors. **Scand J Rheumatol 1988; S75: 89-92**

15. Venables PJW, Baboonian C, Horsfall AC, Halliday D, Maini RN, Teo CG, **Mageed RA**, Millman G. The response to Epstein-Barr virus infection in Sjogren's syndrome. **J Autoimm 1989; 2: 439-48.**

16. Shokri F, **Mageed RA**, Jefferis R, Kitas GD, Katsikis P, Moutsopoulos HM. Monoclonal anti-cross-reactive idiotype antibodies as possible probes for lymphoproliferation in primary Sjogren's syndrome. **Br J Rheumatol 1989; 28: 458-9.**

17. Venables PJ, Baboonian C, Horsfall AC, Halliday D, Maini RN, Teo CG, **Mageed RA**, Millman G. The response of Epstein-Barr virus infection in Sjogren's syndrome. In: **Sjogren's syndrome a model for understanding autoimmunity. Ed. N Talal; Academic Press Ltd. 1989; pp: 131.**

18. Jefferis R, **Mageed RA**. The specificity and reactivity of rheumatoid factor with human IgG. **Monographs in Allergy 1989; 26: 45-60.**

19. Abderrazik M, Moynier M, Couret M, Combe B, **Mageed RA**, Jefferis R, Sany J, Brochier J. Frequency of rheumatoid factor-producing precursor B-cells in rheumatoid arthritis. Idiotypic studies. **Septime Symposium International D'Immuno-Rheumatologie. Eds J Clot, J Sany, J Brochier. 1989; Pp: 143-7.**

20. Crowley JJ, **Mageed RA,** Silverman GJ, Chen PP, Kozin F, Erger RA, Jefferis R, Carson DA. The incidence of a new human cross-reactive idiotype linked to subgroup V_HIII heavy chains. **Mol Immunol 1990; 27: 87-94.**

21. Shokri S, **Mageed RA,** Tunn E, Bacon PA, Jefferis R. Qualitative and quantitative expression of V_HI associated cross-reactive idiotopes within IgM rheumatoid factor from patients with early synovitis. **Ann Rheum Dis 1990; 49: 150-4.**

22. Kondratowicz GM, Symmons DPM, Bacon PA, **Mageed RA**, Jones EL. Rheumatoid lymphadenopathy: A morphological and immunohistochemical study. **J Clin Pathol 1990; 43: 106-13.**

23. Thompson KM, Randen I, Natvig JB, **Mageed RA**, Jefferis R, Carson DA, Tighe H, Forre Ö. Human monoclonal rheumatoid factors derived from the polyclonal repertoire of rheumatoid synovial tissue: incidence of cross-reactive idiotype and expression of VH and VL subgroups. **Eur J Immunol 1990; 20: 863-8.**

24. **R A Mageed**, D M Goodall, R Jefferis. 1990. A highly conserved conformational idiotope on human IgM rheumatoid factor paraproteins from the Wa cross-reactive idiotype family defined by a monoclonal antibody. **Rheumatol Int 10: 57-63.**

25. Brown CMS, Plater-Zyberk C, **Mageed RA**, Jefferis R, Maini RN. Analysis of immunoglobulins secreted by hybridomas derived from rheumatoid synovia; evidence for an oligoclonal B-cell response. **Clin Exp Immunol 1990; 80: 366-72.**

26. Lydyard PM, Quartey-Papafio RP, Broker BM, McKenzie L, Hay FC, Youinou PY, Jefferis R, **Mageed RA**. The antibody repertoire of early human B cells. III. Expression of cross-reactive idiotypes characteristic of certain rheumatoid factors and identifying V_kIII, V_HI, and V_HIII gene family products. **Scand J Immunol 1990; 32: 709-16**

27. Natvig JB, Randen I, Thompson K, Forre Ö, **Mageed RA**, Jefferis R, Carson DA, Tighe H, Pascual V, Victor KD, Capra JD. Probing of the rheumatoid factor (RF) V gene repertoire in rheumatoid arthritis (RA) by hybridoma clones.
Clin Exp Rheumatol 1990; 6(S5): 75-80.

28. **Mageed RA**, Kirwan JR, Thompson PW, McCarthy DA, Holborow EJ. Characterisation of the size and composition of circulating immune complexes in patients with rheumatoid arthritis. **Ann Rheum Dis 1991; 50: 231-236**

29. MacKenzie LE, Youinou P, Hicks R, Yuksel B, **Mageed RA**, Lydyard PM. Auto and polyreactivity of IgM from $CD5^+$ and $CD5^-$ cord blood B-cells. **Scand J Immunol 1991; 33: 329-35.**

30. Deacon EM, Matthews JB, Potts AJC, Hamburger J, **Mageed RA**, Jefferis R. Expression of rheumatoid factor associated cross-reactive idiotopes by glandular B-cells in Sjogren's syndrome. **Clin Exp Immunol 1991; 83: 280-5.**

31. Shokri F, **Mageed RA,** Maziak BR, Jefferis R. Expression of V_HIII-associated cross-reactive idiotype on human B-lymphocytes. Association with staphylococcal protein A binding and staphylococcus aureus Cowan I stimulation. **J Immunol 1991; 146: 936-40.**

32. **Mageed RA**, Kirwan JR, Holborow EJ. Localisation of circulating immune complexes from patients with rheumatoid arthritis in murine spleen germinal centres. **Scand J Immunol 1991; 34: 323-31.**

33. Shokri F, **R A Mageed RA**, G D Kitas GD, P Katsikis P, H M Moutsopoulos HM, R Jefferis R. Quantitation of cross-reactive idiotype positive rheumatoid factor in autoimmune rheumatic diseases. An indicator of clonality and B-cell proliferative mechanisms. **Clin Exp Immunol 1991; 85: 20-27.**

34 **Mageed RA**, MacKenzie LE, Stevenson FK, Yuksel B, Shokri F, Maziak BR, Jefferis R, Lydyard PM. Selective expression of a V_HIV subfamily of immunoglobulin genes in human $CD5^+$ B-lymphocytes from cord blood. **J Exp Med 1991; 174: 109-13.**

35. Silman AJ, Ollier W, **Mageed RA**. Rheumatoid factor production in the unaffected first degree relatives in multicase rheumatoid arthritis families. **J Rheumatol 1991; 18: 512-5.**

36. MacKenzie LE, **Mageed RA,** Youinou PY, Yuksel B, Jefferis R, Lydyard PM. Repertoire of $CD5^+$ and $CD5^-$ cord blood B-cells: Specificity and expression of V_HI and V_HIII associated idiotopes. **Clin Exp Immunol 1992; 88: 107-11.**

37. Abderrazik M, Moynier M, Jefferis R, **Mageed RA**, Combe B, Sany J, Brochier J. Analysis of monoclonal rheumatoid factors obtained from B cell repertoire in rheumatoid arthritis. **Scand J Immunol 1992; 35: 149-57.**

38. Lydyard PM, MacKenzie LE, Youinou PY, Deane M, Jefferis R, **Mageed RA.** Specificity and idiotype expression of IgM produced by $CD5^+$ and $CD5^-$ cord blood B-cell clones. **Ann NY Acad Sci 1992; 651: 527-39.**

39. Mierau R, Gause A, Kuppers R, Michels M, **Mageed RA**, Jefferis R, Genth E. A human monoclonal IgA rheumatoid factor using the VκIV light chain gene. **Rheumatol Int 1992; 12: 23-31.**

40. Newkirk MM, Rauch J, **Mageed RA**, Jefferis R, Posnett DN, Silverman GJ. Restricted immunoglobulin variable region gene usage by hybridoma rheumatoid factors from patients with systemic lupus erythematosus and rheumatoid arthritis.
Mol Immunol 1993; 30: 255-63.

41. Shokri F, **Mageed RA**, Maziak BR, Talal N, Amos N, Williams B, Jefferis R. Lymphoproliferation in primary Sjogren's syndrome: evidence for

selective expansion of a B-cell subset characterised by the expression of cross-reactive idiotype (CRI). **Arthritis Rheum 1993; 36: 1128-36.**

42. Shokri F, **Mageed RA**, Richardson P, Jefferis R. High frequency expression and modulation of autoantibody associated cross-reactive idiotypes in CD5 expressing B-lymphocytes from patients with chronic lymphocytic leukaemia. **Scand J Immunol 1993; 37: 673-9.**

43. Deane M, MacKenzie LE, Stevenson F, Youinou PY, Lydyard PM, **Mageed RA.** The genetic basis of human V_H4 gene family-associated cross reactive idiotype expression in $CD5^+$ and CD^- cord blood B-lymphocyte clones. **Scand J Immunol 1993; 38: 348-58.**

44. Scott BB, Sadigh S, Stow M, **Mageed RA**, Andrew EM, Maini RN. Molecular mechanisms involved in pathogenic anti-mouse red blood cell antibodies (MRBC) in NZB mice. **Clin Exp Immunol 1993; 93: 26-33.**

45. Scott BB, Sadigh S, Stow M, **Mageed RA**, Andrew EM, Maini RN. Anti-mouse red blood cell monoclonal antibodies use functionally rearranged genes from the V_H J558 family and are derived from the CD5 negative B-lymphocyte subpopulation. **Immunol 1993; 79: 568-73.**

46. Shokri F, **Mageed RA**, Jefferis R. A quantitative ELISA for the measurement of rheumatoid factor associated cross-reactive idiotype in serum from patients with rheumatic diseases. **Br J Rheumatol 1993; 32: 862-9.**

47. Lydyard PM, Lamour A, MacKenzie LE, Jamin C, **Mageed RA**, Youinou P. $CD5^+$ B cells and the immune system. **Immunol Lett 1993; 38: 159-66**

48. Shokri F, **Mageed RA**, Richardson P, Jefferis R. Immunophenotypic and idiotypic characterisation of leukaemic B-cells from patients with prolymphocytic leukaemia: Evidence for a selective expression of immunoglobulin variable region (IgV) gene products. **Leukaemia Res 1993; 17: 669-76.**

49. Youinou P, MacKenzie LE, Lamour A, **Mageed RA**, Lydyard PM. Human CD5-positive B cells in lymphoid malignancy and connective tissue disease. **Eur J Clin Invest 1993; 23: 139-50.**

50. Sadigh S, Scott BB, **Mageed RA**, Malcolm A, Andrew EM, Maini RN. Identification of hybridomas derived from mouse $CD5^+$ B-lymphocytes by fluorescent staining for cytoplasmic CD5 expression. **Immunol 1994; 81: 558-63.**

51. **Mageed RA**. The RF antigen. **In: Manual of Biological Markers of Disease. Eds.: WJ van Venrooij and RN Maini. Dordrecht: Kluwer Academic Publishers, The Netherlands; 1994.**

52. Moazzeni M, Mosayebi G, Stevenson FK, Rowe M, Abbot S, **Mageed RA**, Shokri F. Biased utilisation of immunoglobulin variable region heavy and light chain genes by the malignant CD5-negative B-lymphocytes from patients with Burkitt's lymphoma. **Int J Cancer 1994; 58: 226-32.**

53. Scott BB, Sadigh S, Andrew EM, Maini RN, **Mageed RA.** Affinity maturation and isotype switch in clonally related anti-erythrocyte autoantibodies.
Scand J Immunol 1994; 40: 16-21.

54. **R A Mageed RA**, J Vencovsky J, R N Maini RN. Rheumatoid factors and germline genes in rheumatoid arthritis: evidence of an intrinsic B-lymphocyte defect? **Br J Rheumatol 1994; 33: 105-7.**

55. Suleyman S, Thompson KM, Sioud M, Randen I, **Mageed RA**, Natvig JB. Monoclonal antibodies against products of two distinct human V_H3 genes expressed in the early repertoire. **Scand J Immunol 1994; 40: 681-90.**

56. Vencovsky J, **Mageed RA**, Ollier WE, Maini RN. Monozygotic rheumatoid arthritis twin pairs express similar levels of conserved immunoglobulin V genes in polyclonal rheumatoid factors irrespective of disease status.
Scand J Immunol 1995; 42: 147-157

57. Brown CM, Fitzgerald KJ, Moyes S, **Mageed RA**, Williams DG, Maini RN. Sequence analysis of immunoglobulin heavy chain variable region genes from the synovium of a rheumatoid arthritis patient shows little evidence of mutation but diverse CDR3.
Immunol 1995; 84: 367-74.

58. MacGregor AJ, Bamber S, Carthy D, Vencovsky J, **Mageed RA**, Ollier WER, Silman AJ. Heterogeneity of Disease phenotype in monozygotic twins concordant for rheumatoid arthritis. **Br J Rheumatol 1995; 34: 215-20.**

59. MacGregor AJ, Ollier WER, Vencovsky J, **Mageed RA**, Carthy D, Silman AJ. Rheumatoid factor isotypes in monozygotic and dizygotic twins discordant for rheumatoid arthritis. **J Rheumatol 1995; 22: 2203-7.**

60. Harmer IJ, **Mageed RA**, Kaminsky A, Charles P, Bruggemann M, Mackworth-Young C. Chimaeric monoclonal antibodies encoded by the human VH26 gene from naive transgenic mice display a wide range of antigen binding specificities determined. Using chimaeric antibodies from naive transgenic mice. **Immunol 1996; 88: 174-82.**

61. Moyes S, Brown C, Scott BB, Maini RN, **Mageed RA**. Analysis of V_K genes in RA synovial B-lymphocytes provides evidence for both, polyclonal activation and antigen-driven selection. **Clin Exp Immunol 1996; 105: 89-98.**

62. de S Oliveira GG, Izui S, Ravirajan CT, **Mageed RA**, Lydyard PM, Elson CJ, Barker RN. Antigen specificity of red blood cell-reactive monoclonal antibodies from NZB mice. **Clin Exp Immunol 1996; 105: 313-20.**

63. **Mageed RA**, Börretzen M, Moyes SP, Thompson KM, Natvig JB. Rheumatoid factor autoantibodies in health and disease. **Ann NY Acad Sci 1997; 815: 296-311.**

64. **Mageed RA**, Moyes SP, Vencovsky J, Maini RN. Somatic mutation and CDR3 length of immunoglobulin lambda variable region genes in the synovium of patients with rheumatoid arthritis. **Ann NY Acad Sci 1997; 815: 319-23.**

65. Vencovsky J, Maini RN, Ollier WE, **Mageed RA**. Immunoglobulin variable region gene expression in rheumatoid factors in monozygotic twins with rheumatoid arthritis.
Ann NY Acad Sci 1997; 815: 324-6.

66. **Mageed RA**, S P Moyes SP, K M Thompson KM, J B Natvig JB. 1997. Molecular and cellular aspects of human rheumatoid factor production and idiotypes. **In Human Idiotypes in Medicine: Autoimmunity, Infection and Cancer. Editors: Y Shoenfeld, RC Kennedy, S Ferrone; Elsevier Science. 1997; P: 135-155**

67. **Mageed RA**, Adams G, Podhajcer O, Chernajovsky Y. Prevention of collagen-induced arthritis model in mice by gene delivery of soluble p75 tumour necrosis factor receptor. **Gene Therapy 1998; 5: 1584-92.**

68. Hajeer AH, Iazarus M, Turner D, **Mageed RA**, Vencovsky J, Huchinson I, Ollier WE. Functional polymorphisms in the IL-10 promoter region are associated with IgA rheumatoid factor in rheumatoid arthritis. **Scand J Rheumatol 1998; 27: 142-5.**

69. Annekov A, Moyes SP, Eshhar Z, **Mageed RA**, Chernajovsky Y. Loss of original antigenic specificity in T cells to collagen by transduction with a chimeric receptor containing single chain anti-collagen antibody and FcgRIε subunit.
J Immunol 1998; 161: 6604-13.

70. Melero J, Aguilera I, **Mageed RA**, Jefferis R, Tarragó D, Núñez-Roldán A, Sánchez B. The frequent expansion of a subpopulation of B cells that express RF-associated cross-reactive idiotypes: evidence from analysis of a panel autoreactive monoclonal antibodies. **Scand J Immunol 1998; 48: 152-8.**

71. Moyes SP, Maini RN, **Mageed RA**. Differential use of immunoglobulin light chain genes and B lymphocyte expansion at sites of disease in rheumatoid arthritis (RA) compared with circulating B lymphocytes. **Clin Exp Immunol 1998; 113: 276-88.**

72. Chernajovsky Y, Annekov A, Herman C, Triantaphylopoulos K, Gould D, Draja H, Moyes SP, Croxford JL, **Mageed RA**, Podhajcer O, Baker D. Gene therapy for rheumatoid arthritis: Theoretical considerations. **Drugs and Ageing 1998; 12: 29-41**

73. Abadi J, Friedman J, **Mageed RA,** Jefferis R, Rodriguez-Barradas M, Pirofski L-A. Human antibodies elicited by a 23-valent pneumococcal polysaccharide vaccine express idiotypic determinants indicative of V_H3 gene segment usage.
J Infect Dis 1998; 178: 707-16.

74. Mason AN, Harmer I, **Mageed RA**, Mackworth-Young CG. The BH1 idiotype defines a population of anticardiolipin antibodies closely associated with the antiphospholipid syndrome. **Lupus 1999; 8: 234-9.**

75. Potter KN, Li Y, **Mageed RA**, Jefferis R, Capra JD. Anti-idiotypic antibody D12 and superantigen SPA both interact with human VH3-ecoded antibodies on the external face of the heavy chain involving FR1, CDR2 and FR3.
Mol Immunol 1999; 35: 1179-87.

76. Potter KN, Li Y, **Mageed RA**, Jefferis R, Capra JD. Molecular characterisation of VH1 specific variable region determinant recognized by

anti-idiotypic monoclonal antibodies G6 and G8. **Scand J Immunol 1999; 50: 14-20.**

77. Axford JS, Rees DH, **Mageed RA**, Wordsworth P, Alavi A, Steere A. Increased IgA rheumatoid factor and VH1-associated cross-reactive idiotype expression in patients with Lyme arthritis and neuroborreliosis. **Ann Rheum Dis 1999; 58:757-61.**

78. Williams DG, Moyes S, **Mageed RA**. Rheumatoid factor isotype switch and somatic mutation variants within rheumatoid arthritis synovium. **Immunol 1999; 98: 123-36.**

79. **Mageed RA**, Vencovsky J, Youinou P, Lydyard PM. Polyreactivity and immunoglobulin variable region gene usage in human CD5+ B cells. **Trans Cauc J Immunol 1999; 1: 15-24.**

80. Chernajovsky Y, Dreja H, Daly G, Annenkov A, Gould D, Adams G, Croxford LJ, Baker D, Podhajcer OL, **Mageed RA**. Immuno and genetic therapy in autoimmune diseases. **Genes and Immunity 2000; 1: 295-307.**

81. Suleyman S, Thompson K, **Mageed RA**, Natvig JB. Molecular analysis of idiotopes recognized by anti-VH3 antibodies 7B4, B6 and D12. Human immunoglobulin CDR2 sequences are mimicked by HIV gp120. **Scand J Immunol 2000; 52: 341-7.**

82. Lattesjö H, Burd GP, **Mageed RA**. $CD4^+$ T lymphocytes with constitutive CD40 ligand in pre-autoimmune (NZB x NZW) F1 lupus-prone mice: phenotype and role in autoreactivity. **J Immunol 2000; 165: 4095-104.**

83. Gharagozloo S, Sharifian RA, Stevenson FK, Jefferis R, **Mageed RA**, Shokri F. 2000. Analysis of the expressed immunoglobulin variable region heavy chain gene products in paraproteins from Iranian patients with multiple myeloma. **Pathol Oncol Res 2000; 6: 185-90.**

84. **Mageed RA**, Harmer IJ, Moyes SP, Wynn S, Brüggemann M, Mackworth-Young CG. Rearrangement of the human heavy chain variable region gene V3-23 generates polyreactive antibodies in transgenic mice. **Clin Exp Immunol 2001; 123: 1-8.**

85. Mason AN, **Mageed RA**, Mackworth-Young CG. The effects of a human IgM monoclonal anticardiolipin antibody on pregnancy in a transgenic mouse model. **Lupus 2001; 10: 289-94**

86. Porakishvili N, **Mageed R**, Jamin C, Pers JO, Kulikova N, Renaudineau Y, Lydyard PM, Youinou P. Recent progress in the understanding of B-cell functions in autoimmunity. **Scand J Immunol 2001; 54: 30-8**

87. Vencovsky J, Jarosova K, Ruzickova S, Nemcova D, Niederlova J, Ozen S, Alikasifoglu M, Bakkaloglu A, Ollier WE, **Mageed RA**. Higher frequency of allele 2 of the interleukin-1 receptor antagonist gene in patients with juvenile idiopathic arthritis. **Arthritis Rheum 2001; 44: 2387-91.**

88. Vencovský J, Zd'árský E, Moyes SP, Hajeer A, Ruzicková Š, Cimburek Z, Ollier WE, Maini RN, **Mageed RA**. Polymorphism in the immunoglobulin VH gene V1-69

affects susceptibility to rheumatoid arthritis in subjects lacking the HLA-DRB1 shared epitope. **Rheumatology 2002; 41:401-10.**

89. Youinou P, Lydyard PM, **Mageed RA**. B cells underpin lupus immunopathology. **Lupus 2002; 11: 1-3.**

90. **Mageed RA**, Zack D. The target antigen and pathology of anti-DNA autoantibodies in systemic lupus erythematosus. **Lupus 2002; 11: 783-6.**

91. **Mageed RA**, Isenberg DA. Tumour necrosis factor alpha (TNFa) and anti-TNFa in autoimmune rheumatic diseases and role in the induction of anti-DNA autoantibodies. **Lupus 2002; 11: 850-5.**

92. Jury EC, Kabouridis PS, Abba A, **Mageed RA**, Isenberg DA. Increased ubiquitination and reduced expression of LCK in T lymphocytes from patients with systemic Lupus erythematosus. **Arthritis Rheum 2003; 48:1343-54.**

93. **Mageed RA,** Prud'homme GJ. Immunopathology and the gene therapy of lupus. **Gene Ther 2003; 10: 861-74.**

94. Mackworth-Young CG, Harmer IJ, **Mageed RA**. The role of antigen in the selection of the human V3-23 immunoglobulin heavy chain variable region gene. **Clin Exp Immunol 2003; 134: 420-5.**

95. Jury EC, Kabouridis PS, Flores-Borja F, **Mageed RA,** Isenberg DA. Altered lipid raft-associated signalling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. **J Clin Invest 2004; 113: 1176-87.**

96. Renaudineau Y, Hillion S, Saraux A, ***Mageed RA**, *Youinou P. An alternative exon 1 of the cd5 gene regulates CD5 expression in human B lymphocytes.
Blood 2005; 106: 2781-9. *(Joint last authorship)

97. Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, **Mageed RA.** Decreased Lyn expression and translocation to lipid raft signalling domains in B-lymphocytes from patients with systemic lupus erythematosus. **Arthritis Rheum 2005; 52: 3955-65.**

98. Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, **Mageed RA.** Lyn deficiency in B cells from patients with systemic lupus erythematosus: **Arthritis Rheum 2006; 54: 2037-8.**

99. Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, **Mageed RA.** Altered lipid raft-associated proximal signalling and translocation of CD45 tyrosine phosphatase in B-lymphocyte from patients with lupus disease. **Arthritis Rheum 2007; 56: 291-302.**

100. Taher TE, Tulone C, Fatah R, D'Acquisto F, Gould DJ, **Mageed RA.** Repopulation of B-lymphocytes with restricted gene expression using haematopoietic stem cells engineered with lentiviral vectors. **Gene Ther 2008; 15: 998-1006.**

101 Zouali M, **Mageed RA.** Cellular interactions and signalling defects in lupu **Lupus 2008;17: 236-40**.

102. Youinou P, Taher TE, Mankaï A, Berthou C, **Mageed RA**. Anti-CD20 in targeting B-lymphocytes for the treatment of autoimmune diseases. Clinical benefits and insights into the role of B-lymphocytes in disease pathology.

Immunol Endocrine Metabol Agents Med Chem 2008, 8:222-34.

103. **Mageed RA**. New strategies and biological agents in the treatment of autoimmune inflammatory diseases. Progress and challenges.
Immunol Endocrine Metabol Agents Med Chem, 2008, 8: 191-9.

104. Habib HM, Taher TE, DA Isenberg DA, **RA Mageed RA**. Enhanced tumor necrosis factor alpha-mediated apoptosis of T-lymphocyte in patients with systemic lupus erythematosus. **Scand J Rheumatol 2009, 38: 112-20.**

105. Rochas C, Hillion S, Saraux A, **Mageed RA**, Youinou P, Jamin C, Valérie Devauchelle V. Transmembrane BAFF from rheumatoid synoviocytes requires IL-6 to induce the expression of RAG in B lymphocytes. **Arthritis Rheum 2009, 60: 1261-71.**

106. Alard J-E, Dueymes M, **Mageed RA**, Saraux A, Youinou P, Jamin C. CCR5 in association with HSP70 promotes apoptosis induced by anti-HSP60 antibody.

FASEB J 2009; 23: 2772-9.

107. Garaud S, Le Dantec C, Jousse-Joulin S, Hanrotel-Saliou C, Saraux A, **Mageed RA**, Youinou P, Renaudineau Y. IL-6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation. **J Immunol 2009 ; 182: 5623-32.**

108. Youinou P, Taher TE, **Mageed RA**, Renaudineau Y. B-lymphocyte cytokines in autoimmune diseases. **Arthritis Rheum 2009; 60: 1873-80.**

109. Garaud S, Le Dantec C, de Mendoza AR, **Mageed RA**, Youinou P, Renaudineau Y. IL-10 production by B cells expressing CD5 with the alternative exon 1B.

Ann NY Acad of Sci 2009; 1173: 280-5.

110. Taher TE, Parikh K, Flores-Borja F, Mletzko S, Isenberg DA, Maikel P. Peppelenbosch MP, **Mageed RA.** Protein phosphorylation and kinome profiling reveal altered regulation of multiple signalling pathways in B lymphocytes from patients with systemic lupus erythematosus. **Arthritis Rheum 2010; 62: 2412-23.**

111. Seité J-F, Cornec D, Renaudineau Y, Youinou P, **Mageed RA**, Hillion S. Intravenous immunoglobulin promotes apoptosis of mature human B lymphocytes by using CD22 to modulate their antigen receptor. **Blood 2010; 116: 1698-704.**

112. **Mageed RA**, Taher TE, Jawad AS. Disease mechanisms, genetic susceptibility and therapeutic approaches in lupus disease. **In Gene Therapy for Autoimmune and Inflammatory Diseases; Editors: Paul Robbins and Yuti Chernajovsky; Springer (Basel); pp 127-146; 2010**

113. Garaud S, Morva A, Lemoine S, Hillion S, Bordron A, Pers JO, Berthou C, **Mageed RA**, Renaudineau Y, Youinou P. CD5 Promotes IL-10 Production in Chronic Lymphocytic Leukemia B Cells through STAT3 and NFAT2 Activation.
J Immunol 2011; 186: 4835-44.

114. **Mageed RA**, Garaud S, Taher TE, Parikh K, Pers JO, Jamin C, Renaudineau Y, Youinou P CD5 expression promotes multiple intracellular signaling pathways in B lymphocyte. **Autoimmun Rev 2012; 11:795-8.**

115. Alzabin S, Abraham SM, Taher TE, Palfreeman A, Hull D, McNamee K, Jawad A, Pathan E, Kinderlerer A, Taylor PC, Williams R, **Mageed R**. Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway.
Ann Rheum Dis 2012; 71:1741-8.

116. Thabet Y, Cañas F, Ghedira I, Youinou P, **Mageed RA**, Renaudineau Y. Altered patterns of epigenetic changes in systemic lupus erythematosus and auto-antibody production: Is there a link? **J Autoimmun 2012; 39: 154-60.**

117. Bystrom J, Al-Adhoubi N, Al-Bogami M, Jawad AS, Mageed RA. Th17 lymphocytes in respiratory syncytial virus infection. **Viruses 2013; 5:777-91.**

118. Taher TE, Muhammad HA, Rahim A, Flores-Borja F, Renaudineau Y, Isenberg DA, **Mageed RA**. Aberrant B-lymphocyte responses in lupus: inherent or induced and potential therapeutic targets. **Eur J Clin Invest 2013; 43:866-80.**

119. Taher TE, Muhammad HA, Bariller E, Flores-Borja F, Renaudineau Y, Isenberg DA, **Mageed RA**. B-lymphocyte signalling abnormalities and lupus immunopathology. **Int Rev Immunol 2013; 32(4):428-44.**

120. Albogami MM, Jawad AS, **Mageed RA**. Bone loss in osteoporosis and arthritis. Pathogenesis and therapeutic strategies. **Saudi Med J 2014; 35: 224-33.**

121. Bystrom J, Taher TE, Muhyaddin MS, Clanchy F, Mangat P, Jawad AS, Williams RO, **Mageed RA**. Harnessing the therapeutic potential of Th17 cells.
Mediators Inflamm 2015; 2015: 205156.

122. Al-Bogami M, Alkhorayef M, Bystrom B, Akanle OA, Al-Adhoubi N, Jawad AS, **Mageed RA.** Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate.**Saudi Med J 2015 ; 36: 1305-11.**

123. Simon Q, Jacques-Olivier Pers J-O, Cornec D, **Mageed RA**, Hillion S. In-depth characterization of $CD24^{high}CD38^{high}$ transitional human B cells reveals different regulatory profiles. **J Allergy Clin Immunol 2016; 137: 1577-1584.e10.**

124. Taher TE, Bystrom J, Ong VH, Isenberg DA, Renaudineau Y, Abraham DJ, **Mageed RA**. Intracellular B lymphocyte signalling and the regulation of humoral immunity and autoimmunity. **Clin Rev Allergy Immunol. 2017; 53: 237-264.**

125. Bystrom J, Clanchy FI, Taher TE, Al-Bogami MM, Muhammad HA, Alzabin S, Mangat P, Jawad AS, Williams RO, **Mageed RA**. Response to treatment with TNFα inhibitors in rheumatoid arthritis is associated with high levels of GM-CSF and GM-CSF^{+} T lymphocytes. **Clin Rev Allergy Immunol. 2017; 53: 265-276.**

126. Bystrom J, Clanchy FI, Taher TE, Mangat P, Jawad AS, Williams RO, **Mageed RA**. TNFα in the regulation of Treg and Th17 cells in rheumatoid arthritis and other autoimmune inflammatory diseases. **Cytokine 2018; 101: 4-13.**

127. Garaud S, Taher TE, Debant M, Burgos M, Melayah S, Berthou C, Parikh K, Pers JO, Luque-Paz D, Chiocchia G, Peppelenbosch M, Isenberg DA, Youinou P, Mignen O, Renaudineau Y, **Mageed RA**. CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes. **Cell Mol Immunol. 2018;15:158-170.**

128. Taher TE, Ong VH, Bystrom J, Hillion S, Simon Q, Denton CP, Pers JO, Abraham DJ, **Mageed RA**. Defective regulation of autoreactive IL-6 producing transitional B lymphocytes in patients with systemic sclerosis. **Arthritis Rheumatol 2018 Mar;70(3):450-461.**

129. Bystrom J, Clanchy FIL, Taher TE, Al-Bogami M, Ong VH, Abraham DJ, Williams RO, **Mageed RA**. Functional and phenotypic heterogeneity of Th17 cells in health and disease. **Eur J Clin Invest. 2019 Jan;49(1):e13032.**

130. Taher TE, Bystrom J, Mignen O, Pers J-O, Renaudineau Y, **Mageed RA**. CD5 and B lymphocyte responses: multifaceted effects through multitudes of pathways and channels. **Cell Mol Immunol. 2020 Nov;17(11):1201-1203. doi: 10.1038/s41423-020-0490-z.**

131. Bystrom J, Taher TE, **Mageed RA**. Metabolic pathways underpinning lymphocyte differentiation and responses in health and disease. **Immunometabolism. 2020;2(3):e200024.** https://doi.org/10.20900/immunometab20200024.

132. Al-Bogami M, Bystrom J, Clanchy FIL, Taher TE, Mangat P, Williams RO, Jawad AS, **Mageed RA**. TNFα inhibitors reduce bone loss in rheumatoid arthritis independent of clinical response by reducing osteoclast precursors and IL-20. **Rheumatology (Oxford). 2021 Feb 1;60(2):947-957. doi: 10.1093/rheumatology/keaa551.**

133. Clanchy FIL, Borghese F, Bystrom J, Balog A, Penn H, Hull DN., Wells GMA, Kiriakidis S, Taylor PC, Sacre SM, Williams LM, Stone TW, **Mageed RA***, Williams RO*. TLR expression profiles are a function of disease status in Rheumatoid Arthritis and experimental arthritis. **J Autoimmun 2021 Mar; 118:102597. doi: 10.1016/j.jaut.2021.102597. *Joint senior authors.**

134. Clanchy FIL, Borghese F, Bystrom J, Balog A, Penn H, Taylor PC, Stone TW, **Mageed RA*,** Williams RO*. Disease status in human and experimental arthritis, and response to TNF blockade, is associated with MHC class II invariant chain (CD74) isoform expression. **J Autoimmun. 2022 Apr; 128:102810. doi: 10.1016/j.jaut.2022.102810. *Joint senior authors.**

135. Bystrom J, Taher TE, Henson S, Gould DJ, Rizgar A. **Mageed RA**. Metabolic requirements of Th17 cells and of B cells: Regulation and defects in health and in inflammatory diseases. **Front Immunol. 2022 Oct;13:990794. doi: 10.3389/fimmu.2022.990794.**

136. Beesley CF, Goldman NR, Taher TE, Denton CP, Abraham DJ, **Mageed RA*,** Ong VH*. Dysregulated B cell function and disease pathogenesis in systemic sclerosis. Frontiers in Immunol (Submitted). **Front Immunol. 2023 Jan; 13:999008. doi: 10.3389/fimmu.2022.999008. *Joint senior authors.**

137. Al-Bogami MM, Akanle OA, Aldawood S, Alkhorayef M, Sulieman A, Jawad AS, **Mageed RA.** Comparison of bone mineral density changes between male and female osteoporosis patients using dual energy X-ray absorptiometry scan. **Appl Radiat Isot. 2023 Apr;194:110624. doi: 10.1016/j.apradiso.2022.110624.**

138. Clanchy FIL, Borghese F, Bystrom J, Balog A, Penn H, Hull DN, Mageed RA, Taylor PC, Williams RO. Endotoxin tolerance-associated mechanisms are 1 modulated by the TNF blockade response. **J Autoimmun (Submitted, Mar 2024).**

139. Beesley C, Cole A, Goldman N, Odewale O, Barnett J, Abraham D, Denton C, **Mageed RA*,** Ong V*. Complement perturbation in scleroderma-related interstitial lung disease with emphysema. **(Invited Review by the journal Best Practice and Research Clinical Rheumatology; in preparation). * Joint senior authorship.**

140. Goldman N, Tynan A, Shah S1, Beesley C, **Mageed RA**, Denton C, Ong V. Rituximab and tocilizumab and their effect on lung disease progression in scleroderma. A retrospective cohort study at a single centre. (**In preparation**).

141. Beesley C, Goldman N, Cubuk C, Lewis M, Abraham DA, Denton C, Mageed RA*, Ong V*. Paired transcriptomic analysis of transitional B cells identifies four distinct subsets and reveals the basis of defective peripheral tolerance in systemic sclerosis. **(In preparation) *Joint senior authors.**

142. Muhammad HA, Taher TE, Mullen L, Pastan IH, Chernajovsky Y, Gould DJ, **Mageed RA.** Modulation of B lymphocyte responses by targeted delivery of siRNA through CD22. **(In preparation).**

143. Taher TE, Beesley CF, Bystrom J, Goldman NR, Abraham DJ, Ong VH, **Mageed RA.** B lymphocyte signalling: gyratory pathways and intricate controls, in health and subtle flaws in disease. **Frontiers in Immunol (Invited submission).**

144. Mletzko S, Taher TE, Duchene J, Varin M-M, Fabian Flores Borja F, Warnes G, Yuti Chernajovsky Y, Isenberg DA, **Mageed RA**. A subset of autoreactive B lymphocytes expressing low CD45RB is selectively expanded in patients with lupus. **(In preparation).**

145. Taher TE Warnes G, El Shikh ME, Isenberg DA, **Mageed RA**. Altered CD45RB exression and enhanced PI3kδ phosphorylation underlies dysregulated B lymphocyte function in patients with lupus. **(In preparation).**

146. Nordin NI, Cooper D, D'Acquisto F, Gibbons S, Perrett D, **Mageed RA**. 6-shogaol inhibits production of iNOS, IL-2, IL-23, IL-20 and IL-8, reduces infiltration of PMN and modulates keratinocyte responses in psoriasis. **(In preparation).**

147. Bystrom J, Taher TE, Nordin NI, Rahim A, Jawad AS, **Mageed RA**. The effect of tumour necrosis factor alpha on autoimmunity in lupus disease. (**In preparation).**

148. Taher TE, Gould D, D'Acquisto F, **Mageed RA.** Inhibition of NF-KB by a nemo-binding domain peptide promotes B-lymphocyte death and exacerbates murine lupus disease in vivo **(In preparation).**

National and International Conference Publications:

149. Kirk AP, **Mageed RA**, Archer JR, Currey HLF. Binding of rheumatoid sera to cartilage extracts. **Br J Rheumatol 1984; 23: 136.**

150. Bourne JT, Huskisson EC, Kumar P, **Mageed R**, Wojtulewski JA. Arthritis and coeliac disease. **Br J Rheumatol 23: 147.**

151. Kirk AP, O'Hara B, McMullin J, **Mageed RA**, Menashi S, Archer JR, Currey HLF. An aggregate binding factor in cartilage. **Br J Rheumatol 1985; 24: 97.**

152. Jefferis R, Jose S, **Mageed RA**, Griffiths HR, Lunec J. Free radical induced denaturation of human IgG. **Clin Rheumatol 1987; S6: 117.**

153. **Mageed RA**, Jefferis R. Analysis of rheumatoid factor idiotypy in relation to molecular specificity. **Clin Rheumatol 1987; S6: 135**

154. **Mageed RA**, Tunn EJ, Shokri F, Bacon PA, Jefferis R. Structural analysis of rheumatoid factor in an early synovitis clinic. **Br J Rheumatol 1987; S25: 35.**

155. Jefferis R, **Mageed RA**. 1987. Epitope specificity and idiotypy of rheumatoid factors. **Scand J Rheumatol 1987; S68: 9.**

156. **Mageed RA**, Jefferis R. Structural analysis of rheumatoid factors in essential mixed cryoglobulinaemia (EMC) and rheumatoid arthritis (RA). **Scan J Rheumatol 1987; S68: 13.**

157. Crowley JJ, **Mageed RA**, Silverman GJ, Jefferis R, Chen PP, Carson DA. Structural and genetic analysis of a new cross-reactive idiotype (CRI) associated with human rheumatoid factor heavy chains. **Arthritis Rheum 1988; S31: 47.**

158. **Mageed RA**, Tunn EJ, Shokri S, Bacon PA, Jefferis R. Structural analysis of rheumatoid factor in an early synovitis clinic. **Br J Rheumatol 1987; 25: 35.**

159. **Mageed RA**, Jefferis R. Analysis of immunoglobulin variable region gene usage in rheumatoid factors: possible relationship to genetic predisposition in rheumatoid arthritis. Workshop proceedings. **Disease Markers 1987; 6: 57**

160. **Mageed RA**, Tunn E, Bacon PA, Jefferis R. IgG subclass specificity of IgM rheumatoid factors in early synovitis clinic patients. **Br J Rheumatol 1988; (suppl 1) 27: 35.**

161. **Mageed RA**, R Jefferis R. The major human RF cross-reactive idiotype require heavy and light chain as well as conformational idiotopes. **Br J Rheumatol 1988; (suppl 1) 27: 36**

162. Shokri F, **Mageed RA**, Holder R, Jefferis R. A quantitative ELISA for germline encoded RF in RA patients. **Br J Rheumatol 1988; (suppl 1) 27: 36.**

163. Shokri F, Tunn E, **Mageed RA**, Bacon PA, Jefferis R. Quantitative and qualitative evaluation of IgM-RF in RA and associated clinical subsets. **Br J Rheumatol 1988; (suppl 1) 27: 56.**

164. **Mageed RA**, Jefferis R. Rheumatoid factors and staphylococcal protein A have an apparently common binding specificity for human IgG. **Br J Rheumatol 1988; (suppl) 27: 58.**

165. Tunn E, Salmon M, **Mageed R**, P A Bacon PA. Remission in early rheumatoid arthritis. **Br J Rheumatol 1988; (suppl) 27: 62.**

166. Plater-Zyberk C, Brown CMS, Johnson JW, Maini RN, **Mageed RA**, Jefferis R. Hybridomas from rheumatoid synovium express CD5 antigen and show restricted gene usage. **Br J Rheumatol 1988; (suppl 2) 27: 120.**

167. **Mageed RA**, Kirwan JR, Thompson P, McCarthy DA, Holborow EJ. Size and composition of circulating immune complexes (CICs) in articular and extraarticular rheumatoid arthritis. **Br J Rheumatol 1988; (suppl 2) 27: 54.**

168. **Mageed RA**, Kirwan JR, Holborow EJ. Localisation of circulating immune complexes from patients with rheumatoid arthritis in murine spleen germinal centres. **Br J Rheumatol 1988; (suppl 2) 27: 53.**

169. **Mageed RA**, Jefferis R. 1988. Rheumatoid factors and staphylococcal protein A have an apparently common binding specificity for human IgG. **Br J Rheumatol 1988; (suppl) 27: 58.2**

170. Shokri F, **Mageed RA**, Kitas GD, Moutsopoulos HM, Jefferis R. The level of rheumatoid factor-associated cross-reactive idiotopes in Sjogren's syndrome, rheumatoid arthritis, systemic lupus erythematosus and healthy individuals. **Br J Rheumatol 1989; (suppl 1) 28: 40.**

171. Silman AJ, **Mageed R**, Ollier WER. Class specific rheumatoid factors in first degree relatives of probands with rheumatoid arthritis. **Br J Rheumatol 1989; (suppl 2) 28: 24.**

172. Kondratowicz G, **Mageed RA**, Bryant FJ, Jefferis R, Plewes PL. A quantitative immunohistological study of plasma cells producing germlinePL gene encoded RF in rheumatoid and osteoarthritic synovia. **Br J Rheumatol 1990; (suppl 1) 29: 13.**

173. Natvig JB, Pascual V, Victor KD, Randen I, Thompson K, Forre O, Capra JD, **Mageed RA,** Jefferis R, Carson DA, Tighe H. Probing the rheumatoid factor (RF) V gene

repertoire in rheumatoid arthritis (RA) by hybridoma clones. **Scand J Immunol 1990; 32: 408.**

174. Plater-Zyberk C, Brown CMS, **Mageed RA**, Maini RN. B-cell hybridomas derived from rheumatoid synovium express CD5 antigen and cross-reactive idiotype. **Clin Rheumatol 1990; 9: 580.**

175. Shokri F, Mageed RA, Jefferis R. Selective stimulation of different subsets of B-cells by SAC and EBV as evidenced by the expression of cross-reactive idiotype. **Scand J Immunol 1990; 32: 414.**

176. Shokri F, **Mageed RA**, Maziak R, Talal N, Moutsopoulos H, Williams BD, Jefferis R. Lymphoproliferation in primary Sjogren's syndrome: evidence for selective expansion of a B-cell subset characterised by the expression of cross-reactive idiotypes. **Clin Exp Rheumatol 1990; (S-5) 8: 99.**

177. Deacon EM, Matthews JB, Potts AJB, Hamburger J, **Mageed RA**, Jefferis R. Expression of cross-reactive idiotypes on rheumatoid factors by glandular B-cells in Sjogren's syndrome. **Clin Exp Rheumatol 1990; (S-5) 8: 98.**

178. MacKenzie LE, **Mageed RA**, Youinou PY, Hicks R, Jefferis R, Lydyard PM. Auto antibody specificity and idiotype expression in $CD5^+$ and $CD5^-$ cord blood B-cells. **Clin Exp Rheumatol 1990; 8 (S-5): 108.**

179. MacGregor AJ, Carthy D, **Mageed R**, Ollier WER, Silman AJ. Lack of concordance for rheumatoid factor positivity in a nationwide study of twins with rheumatoid arthritis. **Br J Rheumatol 1991; 30 (Suppl 2): 58.**

180. **Mageed RA**, Brown CMS, Deane M, Katsikis P, Maini RN. Molecular and serological analysis of the B-lymphocyte repertoire in rheumatoid arthritis synovia. **Clin Rheumatol 1992; 11: 129.**

181. Sadigh S, Scott BB, Andrew E, **Mageed RA**, Maini RN. Antigen induced immunoglobulin isotype switch and somatic mutation in the variable region genes of $CD5^+$ B-lymphocytes. **Br J Rheumatol 1992; 26: 187.**

182. **Mageed RA**, Moyes S, Brown CMS, Maini RN. Analysis of the B-lymphocyte repertoire in RA synovia. **Br J Rheumatol 1992; 26: 205.**

183. Scott BB, Sadigh S, Stow W, **Mageed RA**, Andrew EM, Maini RN. Molecular mechanisms resulting in pathogenic anti-mouse red blood cell antibodies (MRBC) in NZB mice. **Arthritis Rheum 1992; 35: S169.**

184. Sadigh S, Scott BB, **Mageed RA**, Andrew EM, Malcolm AD, Maini RN. The molecular and cellular basis of anti-ds DNA antibodies in autoimmune BW mice. **Arthritis Rheum 1992; 35: S169.**

185. Tzioufas AG, Boumba D, **Mageed RA**, Carson DA, Moutsopoulos HM. Prevalence of cross-reactive idiotypes (CRI) of monoclonal rheumatoid factors in Sjogren's syndrome (SS). Relevance of V_HI and V_HIIIb associated CRI with lymphoproliferation of SS. **Clin Rheumatol 1993; 12: 7.**

186. Scott BB, Sadigh S, **Mageed RA**, Andrew EM, Maini RN. Molecular analysis of pathogenic anti-mouse red blood cell antibodies in NZB mice. **Clin Rheumatol 1993; 12: 8.**

187. Katsikis PD, Murison JG, Page TH, **Mageed RA**, Moutsopoulos HM, Feldmann M, Maini RN. $CD5^+$ B-lymphocytes and rheumatoid factor associated G6 cross-reactive idiotype in primary Sjogren's syndrome patients. **Clin Rheumatol 1993; 12: 32.**

188. **Mageed RA**, Vencovsky J, Ollier WE, Maini RN. Immunoglobulin variable region gene expression in rheumatoid factors (RF) in homozygotic twins with RA. **Br J Rheumatol 1993; 32 (suppl 2): 10.**

189. Vencovsky J, **Mageed RA**, Ollier WER, Maini RN. Immunoglobulin variable region gene use in monozygotic twins with rheumatoid arthritis. **Clin Rheumatol 1993; 32: 38.**

190. **Mageed RA**, Scott BB, Sadigh S, Andrew EM, Maini RN. Genetic and cellular analysis of haemolytic autoantibody production in NZB mice. **Br J Rheumatol 1993; 32 (suppl 2): 29.**

191. Moyes SP, **Mageed RA**, Brown CM, Maini RN. Genetic analysis of synovial antibody repertoire. **Br J Rheumatol 1993**; **32 (suppl 2): 9.**

192. Adebajo AO, **Mageed RA**, Hazleman BL. Rheumatoid factor-associated cross-reactive idiotype (CRI) in patients with tropical infections. **Br J Rheumatol 1995; 34 (suppl 1): 34.**

193. MacGregor AJ, Bamber S, Carthy D, Vencovsky J, **Mageed RA**, Ollier WE, Silman AJ. Heterogeneity of disease phenotype in monozygotic twins concordant for rheumatoid arthritis. **Br J Rheumatol. 1995; 34(3):215.**

194. Burd GB, Maini RN, Mageed RA. Different patterns of cytokine and CD40-ligand expression in spleen germinal centres of NZB/W F1 mice compared with normal CBA mice. **Br J Rheumatol 1996; 35 (suppl 1): 5.**

195. Harmer IJ, **Mageed RA**, Brüggemann M, Mackworth-Young CG. A single anti-DNA-related V_H gene encodes for multiple specificities: the influence of the light chain. **Br J Rheumatol 1996; 35 (suppl 1): 23.**

196. Moyes SP, Mageed RA, Maini RN. Somatic mutation and gene fingerprinting of immunoglobulin lambda light chains in the synovium of patients with rheumatoid arthritis. **Br J Rheumatol 1996; 35 (suppl 1): 172.**
197. Hajeer AH, Iazarus M, Turner D, **Mageed RA**, Vencovsky J, Sinnott P, Huchinson IV, Ollier WE. 1IL-10 promoter region polymorphisms are associated with disease expression in rheumatoid arthritis. **Arthritis Rheum 1997; 40: S158.**

198. Jury EC, Kabouridis PS, Nye KE, **Mageed RA**, Isenberg DA. Diminished Expression of LCK in T Lymphocyte Lipid Rafts from Patients with Systemic Lupus Erythematosus (SLE). **Rheumatology 2002; 41: 110.**

199. Jury EC, Kabouridis PS, Flores-Borja F, **Mageed RA**, Isenberg DA. Abnormal co-localisation of CD45 and lipid rafts is associated with reduced LCK expression in T cells from patients with SLE. **Arthritis Rheum 2003; 48: S193**.

200. Vencovský J, Zďárský E, Moyes SP, Hajeer A, Ruzicková Š, Cimburek Z, Ollier WE, Maini RN, **Mageed RA**. Polymorphism in the immunoglobulin VH gene V1-69 affects susceptibility to rheumatoid arthritis in subjects lacking the HLA-DRB1 shared epitope. **Rheumatology 2002; 41: 401.**

201. Jury EC, Kabouridis PS, Flores-Borja F, **Mageed RA**, Isenberg DA. CD45 is abnormally associated with lipid rafts in T lymphocytes from patients with systemic lupus erythematosus. **Rheumatology 2003; 42, 5.**

202. Williams RO, Ahmed S, Isenberg DA, **Mageed RA**. Deficiency in A-Kinase anchor protein expression in peripheral blood leukocytes from patients with SLE. **Rheumatology 2003; 42: 73.**

203. Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, **Mageed R**. Analysis of lipid raft-associated signalling molecules in B cells from normal and patients with SLE. **Rheumatology 2003; 42: 72-73.**

204. Jury EC, Kabouridis PS, Flores-Borja F, **Mageed RA**, Isenberg DA. (2004). Altered lipid raft expression and associated signalling in T lymphocytes from patients with systemic lupus erythematosus (SLE). **Rheumatology 2004; 43: 24.**

205. Flores-Borja F, Kabouridis PS, Jury E, Isenberg DA, **Mageed RA**. Atypical co-localisation of CD45 and Lyn to lipid raft signaling domains correlates with B-lymphocyte hyper responsiveness in patients with lupus. **Rheumatology 2004; 43: 108.**

206. Flores-Borja F, Kabouridis PS, Jury E, Isenberg DA, **Mageed RA.** Translocation of CD45 to lipid raft signalling domains and abnormal relocation during B-lymphocyte activation in SLE. Rheumatology **2005; 44, I17.**

207. Jawad ASM, Mangat M, Perry JD, **Mageed RA.** Anti-TNFα-based therapy in rheumatoid arthritis (RA): Mechanisms of action and possible causes of non-responsiveness. **Rheumatology 2007; 47: II37-II38.**

208. Mletzko S, Flores-Borja F, Taher T, Isenberg DA, **Mageed RA.** Differential CD45 isoform expression contributes to B-cell hyperactivity in patients with systemic lupus erythematosus (SLE). **British Society for Immunology, 2007**.

209. Mletzko S, Varin MM, Duchene J, Taher T, Warnes G, Jawad AS, Isenberg DA, **RA Mageed.** Altered membrane expression levels of distinct CD45RB isoforms are associated with B cell hyperactivity in systemic lupus erythematosus (SLE). **Immunology 2008; 125: 41.**

210. Jawad ASM, Taher TE, Rahim A, D'Acquisto F, Gould D, **Mageed RA**. Selective targeting of the canonical or alternative NF-κB pathway reveals new insights into mechanisms of B-lymphocyte survival and selection. **Rheumatology 2009; 48: 130-131.**

211. Mletzko S, Taher T, Flores-Borja F, Isenberg DA, **Mageed RA.** Altered expression of CD45 influences B lymphocyte responses in patients with systemic lupus erythematosus (SLE). Keystone Symposia, Lymphocyte Activation and Signaling. **Keystone Symposium, (B3), Utah, Snowbird, USA 2007.**

212. Mletzko S, Varin M, Duchene J, Taher T, Warnes G, Jawad AS, Isenberg DA, **RA Mageed.** Altered membrane CD45 isoform expression and intracellular signaling defects in B cell from patients with systemic lupus erythematosus (SLE). **Rheumatology, 2009; 48: 132.**

213. Nordin NI, D'Acquisto F, Gibbons S, Perrett D, **Mageed RA**. Immune-modulatory effects of compounds isolated from Zingiber officinale Roscoe (var. rubrum Theilade) on immune mechanisms associated with psoriasis. **Immunology; 2010; 131: 65.**

214. Nordin NI, D'Acquisto F, Gibbons S, Perrett D, **Mageed RA**. Immune-modulatory Effects of Compounds Isolated from *Zingiber officinale* Roscoe (var. *rubrum Theilade*) on Immune Mechanisms Associated with Psoriasis. **Immunology 2010; 131: 65.**

215. Muhammad HA, Chernajovsky Y, Taher TE, Gould DJ, **Mageed RA.** Therapeutic targeting of pathogenic B lymphocytes using antibody-delivered siRNA. **3rd Int Meeting on Gene therapy 2011.**

216. Nordin NI, Cooper D, D'Acquisto F, Gibbons S, Perrett D, **Mageed RA.** Potent anti-inflammatory compounds identified in *Zingiber officinale* Roscoe var. *rubrum Theilade*: Mechanisms of action in psoriasis. **3rd Int Meeting on Gene therapy 2011.**

217. Nordin NI, D'acquisto F, Gibbons S, Perrett D, **Mageed RA.** Potent anti-inflammatory compounds identified in Zingiber officinale Roscoe var. rubrum Theilade: Mechanisms of action in psoriasis. **Planta Med 2011; 77: PM92.**

218. Muhammad HA, Taher T, Mullen L, Taher TE, Gould DJ, **Mageed RA.** Generation of a secreted scFv for specific delivery of siRNA to B-lymphocytes. **Human Gene Therapy 2013; 24: A36.**

219. Mittal GA, **Mageed RA,** Chernajovsky Y**.** Human (H161R) IL-17F mutant is a dual antagonist of IL-17A and IL-17F. **Rheumatology 2011; 50: 53.**

220. Bystrom J, Taher T, Al-Bogami M, Kelly S, Mangat P, Jawad A, **Mageed RA.** T lymphocyte cytokines distinguish responder from non-responder rheumatoid arthritis patients treated with anti-tumour necrosis factor alpha agents. **Proceedings of the British Pharmacological Society 2013.**

221. Muhammad H, Taher T, Mullen L, Pastan I, Marshall J, Chernajovsky Y, Gould D, **Mageed R**. Development of a novel approach for targeted delivery of siRNA to B lymphocytes with potential application in cancer. **Hum Gene Ther 2014; 25: A55.**

222. Bystrom J, Taher T, Al-Bogami M, Alzabin S, Kelly S, Mangat P, Williams R, Jawad A, **Mageed R**. Cytokine production identified a subset rheumatoid arthritis patients T lymphocytes that is associated with responsiveness to biologic anti-TNF-alpha agents. **Ann Rheum Dis 2014; 73: 356.**

223. Simon Q, Cornec D, **Mageed R**, Pers JO, Hillion S. In-Depth Characterization of CD24(high)CD38(high) Transitional Human B Cells Reveals Different Regulatory Profiles and are Abnormally Distributed in Sjogren's Syndrome. **Scand J Immunol 2015; 81: 378.**

Link to Scopus https://www.scopus.com/authid/detail.uri?authorId=7006516084

Link to Orcid https://orcid.org/0000-0003-1561-784X

Link to Publons

Link Academia https://qmul.academia.edu/RizgarMageed

Link to google scholar
Others